In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EndoBionics Inc.

Latest From EndoBionics Inc.

Cardio3: Moving from Science Project to Business Model in Stem Cells

Cardiac stem cell therapy for regenerating diseased heart tissue has been long on promise but short on delivery. A Belgian incubator and start-up hope to finally bring this treatment to market.

BioPharmaceutical Business Strategies

EndoBionics Inc.

EndoBionics Inc.'s wire-guided microneedle catheter can traverse the vascular system to inject drugs into deep tissues and major organs, areas that have heretofore been hard to reach in a minimally invasive manner. The company's long-term goal is regenerative medicine, but EndoBionics will seek nearer-term revenues from a first application in coronary restenosis, positioning its MicroSyringe as an alternative to drug-eluting stents.

BioPharmaceutical Medical Device

Start-Up Previews (2/05)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Convergence: What's Next at the Nexus?, features profiles of Direct-Haler, EndoBionics, Polymerix and X-Cell Medical. Plus these Start-Ups across Health Care: Discovery Genomics, FoldRx and Neuronetics.

Convergence: What's Next at the Nexus?

Convergence is the great hope of pharmaceutical and device companies hoping to enter into new high growth markets with differentiated products. Drug-eluting stents turned a stagnant product into a thriving $6 billion market, and now companies are trying to find the next large opportunity that combines devices and drugs. They're looking at many kinds of implantable devices that incorporate biomaterials and drugs to achieve site specific drug delivery, in cardiovascular disease, peripheral vascular disease, ophthalmology, orthopedics, wound healing, and anti-infection.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Medical Devices
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • EndoBionics Inc.
  • Senior Management
  • Kirk Seward, PhD, CTO
  • Contact Info
  • EndoBionics Inc.
    Phone: (510) 346-8190
    14460 Doolittle Dr.
    San Leandro, CA 94577